Use of Clomiphene for Infertility in the Polycystic Ovary Syndrome

Background : The polycystic ovary syndrome is a common cause of infertility. Clomiphene is the current first-line infertility treatment in women with the polycystic ovary syndrome. Objective : To observed effect of clomiphene therapy in infertile women with polycystic ovary syndrome. Methodology : In this cross-sectional study we enrolled 210 infertile women aged 25 – 35 years diagnosed as polycystic ovary syndrome. Participants who had normal urine cavity and sperm concentration of at least 20 million/ml of her husband were prescribed clomiphene for 6 months. Medication was discontinued when pregnancy was confirmed and participants were followed until delivery. Results : After 6 months treatment 85(40.5%) patient was conceived. Live birth was 44(20.9%) of 210 subjects. Among pregnancies multiple (twin) birth was 12(5.7%). First trimester pregnancy loss was 41(19.5%). After having 6 months of therapy there was no pregnancy in125 (59.5%) patients. Conclusions : Clomiphene is safe and cost effective medicine in achieving live birth in infertile women with polycystic ovary syndrome. Northern International Medical College Journal Vol.7(1) Jul 2015: 94-96

[1]  K. Barnhart,et al.  Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. , 2014, The New England journal of medicine.

[2]  M. Patil,et al.  Polycystic ovaries and infertility: Our experience , 2008, Journal of human reproductive sciences.

[3]  Huiman X Barnhart,et al.  Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. , 2007, The New England journal of medicine.

[4]  M. Eijkemans,et al.  A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. , 2006, Human reproduction update.

[5]  R. J. Chang,et al.  Hirsutism and acne in polycystic ovary syndrome. , 2004, Best practice & research. Clinical obstetrics & gynaecology.

[6]  Mary E D'Alton,et al.  Obesity, obstetric complications and cesarean delivery rate--a population-based screening study. , 2004, American journal of obstetrics and gynecology.

[7]  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. , 2004, Fertility and sterility.

[8]  J. L. San Millán,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain* , 1999 .

[9]  L. Bisanti,et al.  Body mass index and delayed conception: a European Multicenter Study on Infertility and Subfecundity. , 2000, American journal of epidemiology.

[10]  D. Driscoll,et al.  Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Hull Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. , 1987, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.